Xencor (XNCR) reported $126M in revenue for fiscal 2025, +13.7% year on year. That ranks #2845 by revenue among 2853 SEC filers and #321 in Healthcare. It posted a net loss of −$91.9M for the same year. Revenue has grown 1.6% a year on average since 2016 ($109M then). The fiscal 2025 balance sheet shows $875M in total assets, $54.1M in cash and $76.5M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $126M | +13.7% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$178M | +$906,000 | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$91.9M | +$141M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$135M | +$67.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.2M | −48.3% | FY20252025-12-31 |
| Total assetsAssets | $875M | −8.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $636M | −6.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $54.1M | +32.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $76.5M | −33.6% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $4.5M | −$129M | Open → |
| Q2 20262026-06-30 | $51.2M | −$21.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Xencor Inc
- Ticker
- XNCR
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001326732
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| RidgetechRDGT | $132M | −$1.3M |
| Natural Alternatives InternationalNAII | $130M | −$13.6M |
| Niagen BioscienceNAGE | $129M | $17.4M |
| XencorXNCR | $126M | −$91.9M |
| Monte Rosa TherapeuticsGLUE | $124M | −$38.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Xencor — Key figures |url=https://companiesranked.com/en/company/xencor |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Xencor — Key figures. CompaniesRanked. https://companiesranked.com/en/company/xencorBibTeX
@misc{companiesranked-en-company-xencor-2026,
author = {{CompaniesRanked}},
title = {{Xencor — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/xencor}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001326732-26-000015 · February 25, 2026
{{cite web |title=Xencor — Key figures — 10-K (0001326732-26-000015) |url=https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/xncr-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.